First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013

Mailles, Alexandra; Blanckaert, K.; Chaud, P.; Werf, Sylvie van der; Lina, Bruno; Caro, Valérie; Campese, C; Guéry, B.; Prouvost, Hélène; Lemaire, Xavier; Paty, Marie-Claire; Haeghebaert, S.; Antoine, D; Ettahar, N.; Noël, Harold; Behillil, Sylvie; Hendricx, S.; Manuguerra, Jean Claude; Enouf, Vincent; Ruche, Guy La; Semaille, Caroline; Coignard, B.; Lévy-Brühl, Daniel; Weber, Friedemann; Saura, C.; Che, D.

doi:10.2807/ese.18.24.20502-en

Cited by 122 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[10]. Even for KTx recipients infected with SARS and MERS, the treatment options are limited [3][4][5]. Therefore, enhancing personal protection precautions, early identification, and timely management of affected cases are of crucial importance.…”

Section: Discussionmentioning

confidence: 99%

“…Immunosuppression after transplantation renders kidney transplant (KTx) recipients susceptible to a variety of viral pathogens. Several cases of transplant recipients with SARS-CoV or Middle East respiratory syndrome coronavirus (MERS-CoV) infection have been reported [3][4][5]. However, epidemiological and clinical information characterizing SARS-CoV-2 infections in KTx recipients remains unknown.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Identification of Kidney Transplant Recipients with Coronavirus Disease 2019

et al. 2020

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a novel and lethal infectious disease, posing a threat to global health security. The number of cases has increased rapidly, but no data concerning kidney transplant (KTx) recipients infected with COVID-19 are available. To present the epidemiological, clinical, and therapeutic characteristics of KTx recipients infected with COVID-19, we report on a case series of five patients who were confirmed as having COVID-19 through nucleic acid testing (NAT) from January 1, 2020 to February 28, 2020. The most common symptoms on admission to hospital were fever (five patients, 100%), cough (five patients, 100%), myalgia or fatigue (three patients, 60%), and sputum production (three patients, 60%); serum creatinine or urea nitrogen levels were slightly higher than those before symptom onset. Four patients received a reduced dose of maintenance immunosuppressive therapy during hospitalization. As of March 4, 2020 NAT was negative for COVID-19 in three patients twice in succession, and their computed tomography scans showed improved images. Although greater patient numbers and long-term follow-up data are needed, our series demonstrates that mild COVID-19 infection in KTx recipients can be managed using symptomatic support therapy combined with adjusted maintenance immunosuppressive therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Identification of Kidney Transplant Recipients with Coronavirus Disease 2019

et al. 2020

View full text Add to dashboard Cite

show abstract

“…EVD management is largely supportive with fluid and electrolyte replacement and symptomatic treatment. Clinical trials have explored treatment options [ 110 , 111 , 112 , 113 , 114 ].…”

Section: Convalescent Plasma Therapy (Cpt)mentioning

confidence: 99%

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Moubarak

Kasozi

Hetta

et al. 2021

Life

View full text Add to dashboard Cite

Novel therapies for the treatment of COVID-19 are continuing to emerge as the SARS-Cov-2 pandemic progresses. PCR remains the standard benchmark for initial diagnosis of COVID-19 infection, while advances in immunological profiling are guiding clinical treatment. The SARS-Cov-2 virus has undergone multiple mutations since its emergence in 2019, resulting in changes in virulence that have impacted on disease severity globally. The emergence of more virulent variants of SARS-Cov-2 remains challenging for effective disease control during this pandemic. Major variants identified to date include B.1.1.7, B.1.351; P.1; B.1.617.2; B.1.427; P.2; P.3; B.1.525; and C.37. Globally, large unvaccinated populations increase the risk of more and more variants arising. With successive waves of COVID-19 emerging, strategies that mitigate against community transmission need to be implemented, including increased vaccination coverage. For treatment, convalescent plasma therapy, successfully deployed during recent Ebola outbreaks and for H1N1 influenza, can increase survival rates and improve host responses to viral challenge. Convalescent plasma is rich with cytokines (IL-1β, IL-2, IL-6, IL-17, and IL-8), CCL2, and TNFα, neutralizing antibodies, and clotting factors essential for the management of SARS-CoV-2 infection. Clinical trials can inform and guide treatment policy, leading to mainstream adoption of convalescent therapy. This review examines the limited number of clinical trials published, to date that have deployed this therapy and explores clinical trials in progress for the treatment of COVID-19.

show abstract

“…2 presents the predicted number of deaths with the ARIMA model and the actual number of death cases. Table 2 illustrates that on 14 September 2020, the number of predicted death cases is 8,99,261 using ARIMA Model of order (2,2,3), where the real number of death cases is 9,44,300. So, from Table 1 and Table 2, the predicted confirmed and death cases are quite close to the real confirmed and death cases for ARIMA model.…”

Section: Regression Analysismentioning

confidence: 99%

“…This virus has a similarity with bat-derived coronaviruses, and it is likely that the virus has spread to human beings through an unidentified intermediate carrier [1]. There are four subtypes of coronaviruses namely α, β, γ and δ coronaviruses, some of which have been affecting humans or animals including birds, mice, pigs, dogs and cats [2][3][4][5]. SARS-CoV-2 is a form of β coronavirus, and it affects people of different severity.…”

Section: Introductionmentioning

confidence: 99%

Forecasting the Spread of COVID-19 and ICU Requirements

et al. 2021

View full text Add to dashboard Cite

<span lang="EN-US">Since December 2019, the world is fighting against coronavirus disease (COVID-19). This disease is caused by a novel coronavirus termed as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This work focuses on the applications of machine learning algorithms in the context of COVID-19. Firstly, regression analysis is performed to model the number of confirmed cases and death cases. Our experiments show that autoregressive integrated moving average (ARIMA) can reliably model the increase in the number of confirmed cases and can predict future cases. Secondly, a number of classifiers are used to predict whether a COVID-19 patient needs to be admitted to an intensive care unit (ICU) or semi-ICU. For this, classification algorithms are applied to a dataset having 5644 samples. Using this dataset, the most significant attributes are selected using features selection by ExtraTrees classifier, and Proteina C reativa (mg/dL) is found to be the highest-ranked feature. In our experiments, random forest, logistic regression, support vector machine, XGBoost, stacking and voting classifiers are applied to the top 10 selected attributes of the dataset. Results show that random forest and hard voting classifiers achieve the highest classification accuracy values near 98%, and the highest recall value of 98% in predicting the need for admission into ICU/semi ICU units.</span>

show abstract

First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013

Abstract: The investigation team 11 1.

Cited by 122 publications

References 31 publications

Identification of Kidney Transplant Recipients with Coronavirus Disease 2019

Identification of Kidney Transplant Recipients with Coronavirus Disease 2019

The Rise of SARS-CoV-2 Variants and the Role of Convalescent Plasma Therapy for Management of Infections

Forecasting the Spread of COVID-19 and ICU Requirements

Contact Info

Product

Resources

About